The successful trials come after Starlink rival AST SpaceMobile also used its newly launched satellites to power a video call ...

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

Somerville gene therapy company bluebird bio, once among the highest-profile biotechs in the Boston area, has agreed to be ...

Hand crews will work over the next year to form a new fuel modification zone in the Bluebird Canyon area of Laguna Beach, the ...

Bluebird bio (BLUE) shares continued their downward descent Monday following news that the company plans to be taken private through a deal valued at up to $96M. Read more here.

There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...

12 years after going public, beleaguered gene therapy company bluebird bio will be sold to private equity groups Carlyle and ...

JPMorgan upgraded Bluebird Bio (BLUE) to Neutral from Underweight without a price target after the company entered into a definitive agreement ...

Verizon and AST have yet again pushed the boundaries of what can be done with mobile devices by successfully trialing a live ...

Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Bluebird Bio (BLUE) to $5 from $40 and keeps an Equal Weight rating on the ...

SOMERVILLE, Mass., February 21, 2025--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird") today announced that it has entered into a definitive agreement to be acquired by funds managed by global ...